Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond analysts' top -and-bottom-line estimates for ResMed (RMD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.